Company intelligence / Profile preview

Silvec Biologics

Gaithersburg, Maryland, United Stateslinkedin.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

Currently in EPA review for their citrus greening solution; greenhouse trials show promising results in reducing bacteria levels; field trials planned; final EPA approval expected by end of 2025

Therapeutic areas: OtherInfectious Diseases
Modalities: RNA therapiesvirus vectors
Industry: Agriculture & AgTech

Drug pipeline

1 asset

RNA-based vector product

Pre-clinical

Indications: Citrus Huanglongbing (HLB)

Partnerships

U.S. Sugar (license agreement)

Beyond the preview

Go deeper on Silvec Biologics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Silvec Biologics.

Explore the full profile